A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma

被引：1
|
作者：
Luscan, Gerald [1 ]
Paccagnella, Luisa [2 ]
Patel, Krish [3 ]
机构：
[1] Pfizer Int Org, Global Prod Dev, Paris, France
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Swedish Canc Inst, Seattle, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
    de Vos, S
    Fernando, D
    Schenkein, DP
    Rosen, PJ
    BLOOD, 2005, 106 (11) : 267B - 267B
  • [42] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
    Lihua E. Budde
    Adam J. Olszewski
    Sarit Assouline
    Izidore S. Lossos
    Catherine Diefenbach
    Manali Kamdar
    Nilanjan Ghosh
    Dipenkumar Modi
    Waleed Sabry
    Seema Naik
    Amitkumar Mehta
    Shazia K. Nakhoda
    Stephen D. Smith
    Kathleen Dorritie
    Ting Jia
    Song Pham
    Ling-Yuh Huw
    Jing Jing
    Hao Wu
    Wahib S. Ead
    Iris To
    Connie Lee Batlevi
    Michael C. Wei
    Julio C. Chavez
    Nature Medicine, 2024, 30 : 229 - 239
  • [44] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Giri, Pratyush
    Patil, Sushrut
    Ratnasingam, Sumita
    Prince, H. Miles
    Milliken, Samuel
    Meijide, Javier Briones
    Coyle, Luke
    Van der Poel, Marjolein
    Mulroney, Carolyn M.
    Farooqui, Mohammed Z. H.
    Wong, Hansen
    Desai, Rajendra
    Zugmaier, Gerhard
    Mergen, Noemi
    Cannell, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
    Budde, Lihua E.
    Olszewski, Adam J.
    Assouline, Sarit
    Lossos, Izidore S.
    Diefenbach, Catherine
    Kamdar, Manali
    Ghosh, Nilanjan
    Moth, Dipenkumar
    Sabry, Waleed
    Naik, Seema
    Mehta, Amitkumar U.
    Nakhoda, Shazia K.
    Smith, Stephen D.
    Dorritie, Kathleen
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Jing, Jing
    Wu, Hao
    Ead, Wahib S.
    To, Iris
    Batlevi, Connie Lee
    Wei, Michael C.
    Chavez, Julio C.
    NATURE MEDICINE, 2024, 30 (01) : 229 - +
  • [46] Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Petrillo, Alessandra
    Ip, Andrew
    Della Pia, Alexandra
    Gill, Sarvainder
    Zenreich, Joshua
    Gutierrez, Martin
    McNeill, Ann
    Feldman, Tatyana
    Leslie, Lori A.
    Goy, Andre
    HEMASPHERE, 2022, 6 (06):
  • [47] An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
    Moreau, Philippe
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    de la Rubia, Javier
    Facon, Thierry
    Comenzo, Raymond L.
    Fay, Joseph W.
    Qin, Xiang
    Masterson, Tara
    Schecter, Jordan
    Ahmadi, Tahamtan
    San Miguel, Jesus
    BLOOD, 2014, 124 (21)
  • [48] A Phase 1, Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed/Refractory CD19+B-Cell Malignancies
    Garcia, Jacob
    Dehner, Christine
    Teoh, Jeffrey
    Wallis, Wayne
    BLOOD, 2024, 144 : 17501 - 17501
  • [49] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander
    Raza, Muhammed
    Acosta, Jorge
    Mueller, Patrick Y.
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
  • [50] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
    Lesokhin, Alexander M.
    Raza, Muhammed Saleem
    Acosta, Jorge
    Muller, Patrick
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    Service, Myeloma
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345